BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30833639)

  • 1. HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503.
    Gorbatenko A; Søkilde R; Sorensen EE; Newie I; Persson H; Morancho B; Arribas J; Litman T; Rovira C; Pedersen SF
    Sci Rep; 2019 Mar; 9(1):3352. PubMed ID: 30833639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic p95HER2 regulates Na+-HCO3- cotransporter NBCn1 mRNA stability in breast cancer cells via 3'UTR-dependent processes.
    Gorbatenko A; Olesen CW; Loebl N; Sigurdsson HH; Bianchi C; Pedraz-Cuesta E; Christiansen J; Pedersen SF
    Biochem J; 2016 Nov; 473(21):4027-4044. PubMed ID: 27609814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
    Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
    Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB.
    Gao Y; Zhang W; Liu C; Li G
    Sci Rep; 2019 Dec; 9(1):18844. PubMed ID: 31827114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
    Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
    J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF.
    Bianchi E; Bulgarelli J; Ruberti S; Rontauroli S; Sacchi G; Norfo R; Pennucci V; Zini R; Salati S; Prudente Z; Ferrari S; Manfredini R
    Cell Death Differ; 2015 Dec; 22(12):1906-21. PubMed ID: 25857263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGFβ-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER+ breast cancer cells.
    Cesi V; Casciati A; Sesti F; Tanno B; Calabretta B; Raschellà G
    Cell Cycle; 2011 Dec; 10(23):4149-61. PubMed ID: 22101269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-142-3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bach-1 expression.
    Mansoori B; Mohammadi A; Ghasabi M; Shirjang S; Dehghan R; Montazeri V; Holmskov U; Kazemi T; Duijf P; Gjerstorff M; Baradaran B
    J Cell Physiol; 2019 Jun; 234(6):9816-9825. PubMed ID: 30480817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.
    Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H
    Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
    Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of p95HER2 in trastuzumab resistance in breast cancer.
    Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
    J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
    Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
    Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the E-cadherin repressor ZEB1/2.
    Ma P; Ni K; Ke J; Zhang W; Feng Y; Mao Q
    Exp Biol Med (Maywood); 2018 Mar; 243(5):473-480. PubMed ID: 29368542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
    Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
    Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer.
    Piperigkou Z; Franchi M; Götte M; Karamanos NK
    Matrix Biol; 2017 Dec; 64():94-111. PubMed ID: 28797712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theranostic application of
    Cava C; Novello C; Martelli C; Lodico A; Ottobrini L; Piccotti F; Truffi M; Corsi F; Bertoli G; Castiglioni I
    Theranostics; 2020; 10(1):50-61. PubMed ID: 31903105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
    Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.
    Majumder M; Landman E; Liu L; Hess D; Lala PK
    Mol Cancer Res; 2015 Jun; 13(6):1022-33. PubMed ID: 25733698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
    Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
    J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lnc RNA SNHG20 participated in proliferation, invasion, and migration of breast cancer cells via miR-495.
    Guan YX; Zhang MZ; Chen XZ; Zhang Q; Liu SZ; Zhang YL
    J Cell Biochem; 2018 Nov; 119(10):7971-7981. PubMed ID: 29236315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.